ESSA Pharma Inc (EPIX)

[MiamiGent]

EPIX Here comes another. We aren't dead yet :)

EPIX ESSA PHARMA INC
$4.33 +2.61 (+151.76%)
As of Oct-26-2022 12:46:58 PM ET

https://stockcharts.com/h-sc/ui?s=EPIX

Updated Results From The Phase 1/2 Study Of ESSA's Lead Candidate EPI-7386 In Combination With Enzalutamide Highlighted At The 29th Annual Prostate Cancer Foundation Scientific Retreat

By Benzinga — 7:10 AM ET 10/26/22
EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and durable prostate specific antigen ("PSA") reductions observed in five of six patients

Updated Results from the Phase 1/2 Study of ESSA’s Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
http://archive.fast-edgar.com/20221026/AHZZK62CZ22BMZZ2222G2ZZZMBB9ZZTSEW42/ex991.htm

Company Profile
Sector Health Care
Industry Biotechnology
Company Location Vancouver, BC

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.